Skip to main content

Table 3 Biomarkers as predictors of time to biochemical failure using Cox regression models

From: Evaluation of protein biomarkers of prostate cancer aggressiveness

 

N

Univariate

Multivariate*

Variable

 

HR (95% CI)

P-value

HR (95% CI)

P-value

ACPP

139

0.93 (0.63-1.39)

0.735

1.07 (0.59-1.93)

0.827

ADAM9

152

0.98 (0.63-1.54)

0.944

1.19 (0.75-1.91)

0.462

ALDH1A2

141

0.79 (0.47-1.32)

0.368

1.10 (0.62-1.95)

0.737

CASR

143

1.01 (0.65-1.57)

0.949

0.98 (0.58-1.66)

0.937

CCND1 (nuclear)

142

1.38 (1.01-1.88)

0.042

1.18 (0.87-1.61)

0.296

CCPG1

143

1.19 (0.76-1.88)

0.446

1.14 (0.69-1.86)

0.611

CD34 (avg vess area)

146

1.16 (0.74-1.83)

0.515

1.02 (0.60-1.74)

0.938

CD34 (avg vess per)

146

1.42 (0.91-2.21)

0.123

1.43 (0.84-2.43)

0.188

CD34 (avg lum area)

146

1.45 (0.95-2.22)

0.086

1.37 (0.83-2.27)

0.220

CD34 (avg vasc area)

146

1.02 (0.66-1.60)

0.915

0.89 (0.52-1.53)

0.682

CD34 (MVD)

146

1.11 (0.71-1.73)

0.652

0.97 (0.56-1.67)

0.901

CD34

146

1.11 (0.72-1.71)

0.648

1.04 (0.63-1.71)

0.881

CD44

148

1.07 (0.68-1.68)

0.764

1.06 (0.70-1.60)

0.786

CD44v6

143

1.23 (0.79-1.89)

0.360

1.35 (0.84-2.16)

0.217

CHGA

136

0.50 (0.24-1.04)

0.064

0.56 (0.26-1.21)

0.139

CHMP1A

146

1.31 (0.83-2.08)

0.244

1.35 (0.84-2.20)

0.218

EI24 (stroma)

140

1.24 (0.85-1.82)

0.265

1.36 (0.97-1.91)

0.077

EI24 (tumor)

140

1.32 (0.94-1.87)

0.114

1.32 (0.97-1.79)

0.077

ENO2

145

1.33 (0.92-1.93)

0.135

1.48 (0.92-2.38)

0.108

GADD45B

148

1.11 (0.72-1.73)

0.630

1.18 (0.78-1.77)

0.435

HA (stroma)

150

1.51 (0.99-2.29)

0.055

1.43 (0.95-2.17)

0.090

HAS2

148

1.27 (0.82-1.97)

0.287

1.47 (0.94-2.30)

0.090

HES6

140

0.80 (0.48-1.34)

0.401

0.69 (0.38-1.27)

0.238

HMMR

139

2.01 (1.23-3.30)

0.005

1.98 (1.20-3.29)

0.008

HOXC6

142

1.22 (0.79-1.89)

0.368

1.51 (1.00-2.28)

0.050

HYAL1

147

1.42 (0.92-2.21)

0.116

1.40 (0.87-2.25)

0.163

IGF1

147

1.57 (1.02-2.42)

0.039

1.67 (1.10-2.52)

0.015

IQCK

149

0.90 (0.58-1.40)

0.651

0.90 (0.59-1.38)

0.625

MAP4K4

145

1.44 (0.91-2.28)

0.121

1.76 (1.08-2.86)

0.024

MKI67 (nuclear)

142

1.43 (1.04-1.96)

0.026

1.29 (0.93-1.79)

0.125

PAGE4

145

0.68 (0.45-1.03)

0.069

0.88 (0.57-1.35)

0.566

PLIN2

115

1.21 (0.71-2.09)

0.481

1.07 (0.62-1.86)

0.801

PTEN

144

0.83 (0.54-1.27)

0.393

0.84 (0.51-1.38)

0.493

SIAH2 (nuclear)

144

1.46 (1.07-1.99)

0.016

1.37 (0.94-2.02)

0.104

SMAD4

130

1.76 (1.15-2.71)

0.010

1.73 (1.11-2.70)

0.016

SOX9

145

1.39 (0.90-2.16)

0.137

1.45 (0.93-2.27)

0.101

SPP1

128

1.07 (0.62-1.84)

0.805

0.76 (0.44-1.33)

0.338

SYP

133

0.88 (0.48-1.63)

0.681

0.95 (0.53-1.70)

0.869

TP53_Lab1 (nuclear)

148

1.23 (0.83-1.83)

0.305

1.19 (0.78-1.82)

0.431

TP53_Lab2 (nuclear)

143

0.97 (0.63-1.50)

0.906

0.93 (0.60-1.44)

0.741

  1. MVD, microvessel density.
  2. *Adjusted for age at prostatectomy, pre-op PSA, primary Gleason pattern, and Non-Localized Tumor Indicator.